Abdominal Aortic Aneurysm Market Size, Share, By Treatment Type (Open Surgical Repair (OSR), Endovascular Aneurysm Repair (EVAR), Medical Management), By Product Type (Stent Grafts, Catheters, Delivery Systems and Others), By End-Users (Hospitals, Ambulatory Surgery Centres, Clinics), and By Region – Market Trends, Analysis and Forecast till 2034

Abdominal aortic aneurysm Market was valued at US$ 2.76 billion in 2024 and is projected to grow at a CAGR of 6.0% to reach US$ 4.7 billion by 2034.

AAA stands for Abdominal Aortic Aneurysm, which can be defined as a cardiovascular disease that occurs when there is any abnormal expansion or bulging of the aorta, the prime vessel that supplies blood to organs at the belly, pelvis, and lower limbs. This enlargement usually occurs in the lower part of the aorta, right behind the kidneys. abdominal aortic aneurysm Earns the Nickname "Silent Killer" Because an aneurysm, more often than not, starts slowly and develops very slowly, frequently without symptoms, until it either grows large enough to detect or bursts. It predominantly affects people over 65 years of age, particularly men. The associated risk factors are smoking, high blood pressure, and a family history of the condition. A sufficiently large abdominal aortic aneurysm can present with abdominal or back pain. Rupture leads to severe internal bleeding, which is an emergency. In diagnosis, the most used imaging modalities include ultrasound, CT scan, and MRI. Treatment depends on the size and growth rate of the aneurysm; therefore, for more minor aneurysms, watchful waiting may be appropriate, whereas in more extensive or fast-expanding aneurysms, surgical repair, open surgery or endovascular repair should be undertaken accordingly. The principal targets for the successful management of this potentially lethal illness are regular screening and early identification.

The actual cause of abdominal aortic aneurysm is not usually known, but various circumstances contribute to it. Fatty deposits in the arteries tear down the aortic wall. Genetic variables include certain inherited connective tissue illnesses like Marfan syndrome. The risk rises up drastically beyond the age of 65. Men are about 4-5 times more likely than women to develop abdominal aortic aneurysm. The single most important controllable risk factor that high blood pressure can damage artery walls.

abdominal aortic aneurysm, however, is usually asymptomatic until it enlarges or ruptures. The patient may complain of the following symptoms: pulsing feeling in the belly and deep, persistent pain in the tummy or side of the tummy. Sometimes these are sudden, severe abdominal or back pain, faintness, rapid pulse, and even shock.

Key Drivers of Target Market:   

Demographic shifts and aging populations

• The average aging of the population puts a vast number of subjects at risk from abdominal aortic aneurysm. Such trends create enormous demands for effective treatment options. The increased life expectancy also represents a longer time frame in which an aneurysm has time to develop and possibly rupture, which stresses early detection and treatment.  

Increased Awareness and Early Detection

• Public awareness of the disease increases; with better diagnostics, such as ultrasound scans, most AAAs are now detected earlier before they reach a critical stage and result in potentially fatal ruptures. This allows early intervention before they rupture, and early detection also prompts less invasive treatment options such as EVAR, thereby manifesting market growth.

Developments in Medical Technology

• Designing newer stent grafts that are more anatomically compatible and durable improves treatment outcomes and the quality of life of patients. Improvements in catheters and delivery systems allow stent-grafts to be placed more precisely, with less invasiveness, and with faster recovery times. These improvements help patients and help drive more extensive adoption of EVAR procedures.

Restrains

High Treatment Costs

• One of the major drawbacks is that abdominal aortic aneurysm treatment is expensive, not to mention that minimally invasive EVAR treatment is becoming more expensive. It includes charges for stent grafts, catheters, delivery systems, and inclement hospital stays. High costs can be prohibitive for certain patients, particularly in areas with limited healthcare coverage or high out-of-pocket charges.

Reimbursement Challenges

• The insurance and governmental reimbursement policies do not cover the complete cost of abdominal aortic aneurysm therapy when using new or advanced technology. Rigorous regulatory processes and payment rate limiting is what may impede hospitals and surgeons from having access to innovative treatment alternatives.

Opportunities:

Focus on Cost-Effectiveness

• Affordable stent grafts without compromising on quality will increase accessibility to the market, especially in underserved regions of the world. As treatment becomes more standardized and a hospital utilizes its resources to the fullest, it can cut down costs that are not at the expense of patient care. Increased usage of EVAR procedures, which require a shorter period of hospitalization and recovery time compared to traditional open surgery, will contribute towards decreased healthcare expenditure.

Technological Advancements

• Stent grafts can be technologically improved upon. They treat complex aortic anatomies in an expanded patient population, reduce the risk of long-term complications and secondary interventions, provide long-term performance, and potentially decrease health care expenses related to re-interventions. They allow for easier access to difficult capillaries, thereby making some challenging cases more easily passable. They enable the placement of stent grafts more accurately and potentially with lower complications. Robotic-assisted surgical techniques hold the potential for increased precision and control during treatments in EVAR procedures.

Abdominal Aortic Aneurysm Market is segmented based on Treatment Type, Product Type, End-User, and Region.

Treatment Types Insight

• Open Surgical Repair (OSR)—The age-old warrior, this traditional procedure requires a big incision to access and replace the deficient region with a synthetic graft. While effective, it is a tremendous battle for the patient and necessitates extensive recovery time.
• Endovascular Aneurysm Repair (EVAR)—Like a stealthy ninja, EVAR employs a minimally invasive technique. To fortify the weakening aorta, a stent graft, a miniature samurai sword enclosed in a flexible sheath, is given via catheter and inserted within it. EVAR has faster recovery times and less stress, although it may struggle with complicated anatomy.
• Medical Management - Not every conflict requires brute force. Smaller aneurysms or high-risk patients benefit from a more conservative treatment that includes drugs, lifestyle changes, and continuous monitoring.

Product Type Insights

• Stent Grafts - These are the mainstays of the EVAR battlefield. Design advancements prioritize anatomical compatibility, ensuring the samurai sword is appropriate for the specific aortic terrain. Furthermore, increases in durability and long-term results are comparable to forging a more robust, more resilient blade.
• Catheters - Catheters are a crucial component in the Endovascular Aneurysm Repair (EVAR) procedure used to treat Abdominal Aortic Aneurysms (AAA). They act as a thin, flexible tube inserted into a blood vessel to deliver the stent graft to the weakened area of the aorta.
• Delivery Systems - In Endovascular Aneurysm Repair (EVAR) procedures for Abdominal Aortic Aneurysms (AAA), delivery systems are vital in precisely positioning the stent graft within the weakened aorta. They work in tandem with catheters, guiding and deploying the graft for a successful repair.   
• Others- It includes sterile materials for keeping the field clean, vascular access and closure instruments, patient monitoring devices, and specialist tools for guidewire and catheter manipulations. From the first access to post-operative care, the items enable sterility, patient safety, and exact control throughout the surgery.

End-User Insights

• Hospitals—The majority of abdominal aortic aneurysm engagements take place in these well-equipped fortifications. Every type of vascular center, public, private, and specialist, is essential.
• Ambulatory Surgery Centres As minimally invasive EVAR gets traction, ASCs appear as potential battlegrounds, providing faster turnaround times for appropriate patients. However, their level of engagement is determined by legislation and reimbursement standards.
• Clinics - Clinics serve as outposts, providing pre-operative evaluation, post-operative monitoring, and management for patients with smaller aneurysms undergoing medical treatment.

Regional Insights:

The AAA Market is segmented in the region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

• North America has a well-established healthcare system, including advanced facilities and expert surgeons. High healthcare spending enables more significant adoption of novel technology. abdominal aortic aneurysm is widely recognized, and screening programs have been established.
• Asia Pacific: A rapidly expanding market fueled by rising disposable incomes and an aging population. Raising awareness of abdominal aortic aneurysm and investing in healthcare infrastructure.
• Europe Prioritize cost-effectiveness, which will drive innovation in economical yet practical treatment solutions. A robust regulatory structure ensures patient safety. The aging population drives market growth.
• Latin America Latin America offers a unique set of opportunities and difficulties in the abdominal aortic aneurysm treatment market. The increased prevalence of abdominal aortic aneurysm due to an older population increases the market's potential. Increased public awareness campaigns and enhanced diagnostic technologies can result in earlier detection and intervention. Some governments are financing healthcare infrastructure development, which could improve access to abdominal aortic aneurysm therapy.
• Middle East & Africa region offers a distinct environment in the abdominal aortic aneurysm treatment market. Uneven distribution of healthcare facilities and a shortage of trained vascular surgeons limit access to sophisticated AAA therapy, particularly in Sub-Saharan Africa. Patients may face financial hurdles because to inconsistent or limited insurance coverage for AAA procedures.

Abdominal Aortic Aneurysm Market Report Scope:

Attribute	Details
Market Size 2024	US$ 2.76 Billion
Projected Market Size 2034	US$ 4.7 Billion
CAGR Growth Rate	6.0%
Base year for estimation	2023
Forecast period	2024-2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Treatment Type - Open Surgical Repair (OSR), Endovascular Aneurysm Repair (EVAR), Medical Management By Product Type - Stent Grafts, Catheters, Delivery Systems and Others By End-User - Hospitals, Ambulatory Surgery Centres, Clinics
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For this study segmented the AAA Market report based on By Treatment Type, Product Type, By End-User, and Region

By Treatment Types:

• Open Surgical Repair (OSR)
• Endovascular Aneurysm Repair (EVAR)
• Medical Management

By Product Type:

• Stent Grafts
• Catheters
• Delivery Systems
• Others

By End-User:

• Hospitals
• Ambulatory Surgery Centres
• Clinics

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the abdominal aortic aneurysm market include Medtronic, Cook Medical, MicroPort Scientific Corporation, W. L. Gore & Associates, Bard, Boston Scientific, Abbott Laboratories, Cardinal Health, Jotec GmbH, Lombard Medical, B. Braun Melsungen AG, Symetis SA, and the Society for Vascular Surgery (SVS).

• In March 2024, New Hydrogel Features Increased Capabilities for Treating Aneurysms and Halting Progression.  Traditionally, aneurysms are treated non-invasively by inserting a stent graft to strengthen the arterial walls and keep blood from entering the aneurysm. However, this approach may fail due to leaks between the stent grafts. Scientists at the Terasaki Institute for Biomedical Innovation (TIBI, Los Angeles, CA, USA) have developed a new, injectable shear-thinning hydrogel for the treatment of abdominal aortic aneurysms that not only seals them off more efficiently but also prevents them from growing.
• In August 2023, Researchers at Sant Pau Hospital Research Institute and the Biomedical Research Institute Sant Pau proposed that the Wnt pathway could be a suitable treatment target for abdominal aortic aneurysm. In AngII-infused ApoE−/− mice, trials were conducted with LGK974, a potent and specific porcupine inhibitor, and PRI-724, a selective inhibitor of β-catenin/CBP interaction. LGK974 reduced vascular expression of Axin2, a Wnt/β-catenin/TCF signaling target gene, but did not significantly reduce AngII-induced aortic diameter growth.
• In January 2021, Royal Philips, a global leader in health technology, launched the Philips Abdominal Aortic Aneurysm (AAA) Model, which offers clinicians a more patient-friendly alternative to the existing standard of care for managing AAA patients. Based on 3D ultrasound, the Philips AAA Model provides clinicians with reliable diagnostic information without subjecting patients to high levels of radiation or nephrotoxic contrast chemicals. Philips combines 3D ultrasound with cutting-edge algorithms to revolutionize surveillance of abdominal aortic aneurysms. The Philips Abdominal Aortic Aneurysm (AAA) Model improves diagnostic confidence and patient experience compared to the existing standard of care.

• Medtronic*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Business Strategy Overview
• Cook Medical
• Terumo Corporation
• MicroPort Scientific Corporation
• W. L. Gore & Associates
• Bard
• Boston Scientific
• Abbott Laboratories
• Cardinal Health
• Jotec GmbH
• Lombard Medical
• B. Braun Melsungen AG
• Symetis SA
• Society for Vascular Surgery (SVS).

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description

• Market Definition and Scope

• Executive Summary
  • Key Questions this Study Will Answer
  • Market Snippet, By Treatment Type
  • Market Snippet, By Product Type
  • Market Snippet, By End-User
  • Market Snippet, By Region

• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, By Treatment Type, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Open Surgical Repair (OSR)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Endovascular Aneurysm Repair (EVAR)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Medical Management
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Product Type, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Stent Grafts
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Catheters
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Delivery Systems
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By End-User, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Ambulatory Surgery Centres
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Clinics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • France
    • Germany
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast (US$ Bn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America

• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East

Competitive Landscape

• Heat Map Analysis
  • Medtronic
  • Cook Medical
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • W. L. Gore & Associates
  • Bard
  • Boston Scientific
  • Abbott Laboratories
  • Cardinal Health
  • Jotec GmbH
  • Lombard Medical
  • B. Braun Melsungen AG
  • Symetis SA
  • Society for Vascular Surgery (SVS).

The Last Word

• Future Impact
• About Us
• Contact